Abstract
The authors conducted a pilot randomized, double-blind, placebo- controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 233-235 |
| Number of pages | 3 |
| Journal | Neurology |
| Volume | 54 |
| Issue number | 1 |
| State | Published - Jan 11 2000 |
Fingerprint
Keywords
- Cognitive impairment
- HIV
- Selegiline
ASJC Scopus subject areas
- Neuroscience(all)
Cite this
Transdermal selegiline in HIV-associated cognitive impairment : Pilot, placebo-controlled study. / Sacktor, Ned; Schifitto, G.; McDermott, M. P.; Marder, K.; McArthur, Justin Charles; Kieburtz, K.
In: Neurology, Vol. 54, No. 1, 11.01.2000, p. 233-235.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Transdermal selegiline in HIV-associated cognitive impairment
T2 - Pilot, placebo-controlled study
AU - Sacktor, Ned
AU - Schifitto, G.
AU - McDermott, M. P.
AU - Marder, K.
AU - McArthur, Justin Charles
AU - Kieburtz, K.
PY - 2000/1/11
Y1 - 2000/1/11
N2 - The authors conducted a pilot randomized, double-blind, placebo- controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.
AB - The authors conducted a pilot randomized, double-blind, placebo- controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.
KW - Cognitive impairment
KW - HIV
KW - Selegiline
UR - http://www.scopus.com/inward/record.url?scp=0033958299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033958299&partnerID=8YFLogxK
M3 - Article
C2 - 10636157
AN - SCOPUS:0033958299
VL - 54
SP - 233
EP - 235
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 1
ER -